June 22,
London, ON – Atrium Innovations Inc., a recognized leading developer,
manufacturer and marketer of professionally endorsed, science-based
dietary supplements for the health and nutrition industry, has announced
a multi-year commitment to nutrition research and to a comprehensive
program focusing on metabolic syndrome.
This global effort will be conducted in collaboration with a strategic partner, theInstitute of Nutraceuticals and Functional Foods (INAF). The total current funding for related projects planned and in progress is over $5M, and includes partial support from government agencies.
Based at Université Laval, INAF is comprised of more than 70 researchers from Université Laval and eight other major research institutions in the Province of Quebec. It is among the largest research centers in the world, dedicating all of its research efforts to advancing knowledge in the area of nutrition and health, with an expertise in studying functional food ingredients and dietary supplements. It is widely recognized in Canada and abroad for its innovative and targeted approach, as well as for the quality of its research and the expertise of its members.
“We have a duty to ensure that health care professionals, their patients, and health-conscious consumers have access to safe and effective nutritional products,” said Dr. Barry W. Ritz, Vice President, Scientific and Regulatory Affairs for Atrium Innovations, Inc. “We have aligned ourselves with a strategic academic partner to conduct the most comprehensive program of cutting-edge research on the role of nutritional therapies in managing metabolic syndrome.”
A person is diagnosed with metabolic syndrome when he or she displays a combination of medical conditions known to increase the risk of cardiovascular disease, stroke and diabetes. Such medical conditions include obesity, excess weight, belly fat, insulin resistance, glucose intolerance, hypertension, high blood sugar and high cholesterol levels, as well as pro-inflammatory and pro-oxidative states. Metabolic syndrome has been identified as a major public health crisis worldwide, affecting one in five people and up to 25 per cent of the American population, according to some studies.
Atrium’s research involves gaining a better understanding of metabolic syndrome and investigating the impact of nutrition on the prevention and treatment of silent inflammation associated with this condition. More specifically, its research will emphasize the health benefits of small fruits, the anti-inflammatory mechanisms of specific fish oil fractions in the prevention of cardiovascular disease, probiotics, and systemic enzyme therapy in the management of inflammation, and health promotion.
“We have always believed in the importance of research,” said Pierre Fitzgibbon, President and CEO of Atrium Innovations, Inc. “This investment provides further indication of the depth of our commitment. Applying a more sophisticated science-based approach to our whole spectrum of products, we have the ability to positively affect the quality of life of people by helping them maintain their health and prevent serious diseases.”
For more information on this development, contact Dr. Barry W. Ritz at 610-361-2800 or by email at br@atrium-innovations.com. For more information about Atrium Innovations, Inc., please visit
www.atrium-innovations.com.
